Literature DB >> 11763110

Antihypertensive therapy in critical occupations: studies with an angiotensin II antagonist.

A N Nicholson1, D P Roberts, B M Stone, C Turner.   

Abstract

OBJECTIVE: This study was performed to establish whether an angiotensin II antagonist modulates daytime sleepiness or performance.
METHODS: The central effects of losartan (50 and 100 mg), as well as amlodipine (5 and 10 mg) and promethazine (10 mg), were studied in six healthy volunteers (aged between 20 and 27 (mean 24) yr). Digit symbol substitution, tracking, vigilance, immediate and short-term memory recall, complex reaction time, together with objective (daytime sleep latencies) and subjective measures of sleepiness, were measured 1.0 h before and 0.5, 2.0, 3.5, 5.0, 6.5, and 8.0 h after ingestion. The study was placebo-controlled and double-blind with a six-way crossover design.
RESULTS: No changes in performance or in measurements related to sleepiness were observed with losartan (50 and 100 mg). Amlodipine (10 mg) impaired immediate memory and increased subjective sleepiness at 8.0 h (p < 0.05). Promethazine (10 mg) impaired vigilance and immediate memory recall and increased reaction time (basic and complex) from 2.0 to 6.5 h after ingestion, impaired tracking from 3.5 to 6.5 h and increased subjective sleepiness from 2.0 to 8.0 h (p < 0.05).
CONCLUSION: The study suggests that an angiotensin II antagonist could prove useful for the treatment of hypertension in aircrew.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11763110

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  2 in total

1.  Cognitive enhancement following acute losartan in normotensive young adults.

Authors:  Rasha Mechaeil; Paul Gard; Anne Jackson; Jennifer Rusted
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

2.  The longitudinal association between the use of antihypertensive medications and 24-hour sleep in nursing homes: results from the randomized controlled COSMOS trial.

Authors:  Elisabeth Flo-Groeneboom; Tony Elvegaard; Christine Gulla; Bettina S Husebo
Journal:  BMC Geriatr       Date:  2021-07-18       Impact factor: 3.921

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.